The Food and Drug Administration has determined that it is necessary for manufacturers of cat and dog foods who are covered by the FDA Food Safety Modernization Act Preventive Controls for Animal ...

At the time, the head of the FDA called it "one of the most important actions I could take to advance public health." "If there is a goal to Make America Healthy Again, I can't imagine anything ...

© 2025 NBCUniversal Media, LLCApple®, Apple logo® and App Store® are registered trademarks of Apple Inc.

The RFI for poppy seeds seeks to provide the FDA with a better understanding of whether certain practices increase or reduce the presence of opiate alkaloids on poppy seeds. The agency intends to ...

3 in food and ingested drugs have until January 15, 2027, and January 18, 2028, respectively, to reformulate their products, according to the FDA. Foods imported to the United States also must ...

3 is a synthetic dye that gives candies, sodas, and some medications their cherry hue. "The FDA cannot authorize a food additive or color additive if it has been found to cause cancer in human or ...

Officials cited a statute known as the Delaney Clause, which requires FDA to ban any additive found to cause cancer in people or animals. The dye is known as erythrosine, FD&C Red No. 3 or Red 3.

Arrowhead (ARWR) Pharmaceuticals announced that the U.S. FDA has accepted the New Drug Application for investigational plozasiran for the treatment of familial chylomicronemia syndrome ...

President-elect Donald Trump and his health nominees have not commented on the measure, but a similar effort led by Trump’s first FDA commissioner, Dr. Scott Gottlieb, was sidelined during his ...

The FDA determined that the specific products receiving marketing authorization met the public health standard legally required by the 2009 Family Smoking Prevention and Tobacco Control Act.

Incyte (INCY) and Syndax (SNDX) announced that the FDA has approved Niktimvo in 9 mg and 22 mg vial sizes. The companies expect product to be available for order in the U.S. in early February.

Sanofi has won FDA approval for its sutimlimab for cold agglutinin disease (CAD) at the second time of asking, becoming the first approved therapy for the rare blood disorder in the US.